PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media69125210.18565/pharmateca.2025.5.32-40ReviewsОбзорыReview ArticleModern strategy for managing patients with follicular occlusion syndromeСовременная стратегия ведения пациентов с синдромом фолликулярной окклюзииhttps://orcid.org/0000-0001-6890-2041BotkinaAleksandra S.БоткинаАлександра Сергеевна
Russian Federation

Cand. Sci. (Ned.), Associate Professor, Department of Hospital Pediatrics named after Academician V.A. Tabolin, Pediatric Faculty

к.м.н., доцент кафедры госпитальной педиатрии им. акад. В.А. Таболина педиатрического факультета

botkina@gmail.comhttps://orcid.org/0000-0002-8097-2816GumennayaE. R.ГуменнаяЭ. Р.
Russian Federation
botkina@gmail.comhttps://orcid.org/0009-0009-2656-3278TyukhaevaO. Yu.ТюхаеваО. Ю.
Russian Federation
botkina@gmail.comPirogov Russian National Research Medical UniversityРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаRussian Children’s Clinical Hospital – Branch of Pirogov Russian National Research Medical UniversityРоссийская детская клиническая больница – филиал ФГАОУ ВО РНИМУ им. Н.И. Пирогова2409202532532402309202523092025Copyright ©; 2025, Bionika MediaCopyright ©; 2025, ООО «Бионика Медиа»2025Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/691252

Follicular occlusion syndrome is a chronic inflammatory skin disease that includes hidradenitis suppurativa, acne conglobata, abscessed disruptive folliculitis, Hoffman’s perifolliculitis, epithelial coccygeal passage. The disease has a chronic, continuously relapsing course and has a serious impact on the patient’s quality of life. Early diagnosis and treatment can effectively slow down the progression of the disease, prevent the formation of disfiguring scars, reduce the pathological impact of the disease on the somatic and mental health of patients, and reduce the economic burden. Currently, there is no consensus on the treatment of follicular occlusion syndrome. The article highlights and discusses existing approaches to the treatment of this complex category of patients in the world.

Синдром фолликулярной окклюзии представляет собой хроническое воспалительное заболевание кожи, включающее гнойный гидраденит, конглобатные акне, абсцедирующий и подрывающий фолликулит и перифолликулит Гоффмана, эпителиальный копчиковый ход. Заболевание имеет хроническое непрерывно-рецидивирующее течение и оказывает серьезное влияние на качество жизни пациента. Ранняя диагностика и лечение могут эффективно сдерживать прогрессирование заболевания, предотвращать формирование обезображивающих рубцов, уменьшать патологическое влияние заболевания на соматическое и психическое здоровье пациентов, а также снижать экономическое бремя. В настоящее время нет единого консенсуса относительно терапии синдрома фолликулярной окклюзии. В статье освещаются и обсуждаются существующие в мире подходы к терапии этой сложной категории пациентов.

follicular occlusion syndromeacne conglobatehidradenitis suppurativaabscessed disruptive folliculitisHoffman’s perifolliculitisepithelial coccygeal passageсиндром фолликулярной окклюзииакне конглобатныегнойный гидраденитабсцедирующий и подрывающий фолликулит и перифолликулит Гоффманаэпителиальный копчиковый ходZouboulis C.C., Bechara F.G., Fritz K., et al. S2k guideline for the treatment of hidradenitis suppurativa/acne inversa – Short version. J Dtsch Dermatol Ges. 2024;22(6):868–89. https://dx.doi.org/10.1111/ddg.15412Federico A., Rossi A., Caro G., et al. Are dissecting cellulitis and hidradenitis suppurativa different diseases? Clin Dermatol. 2021;39(3):496–9. https://dx.doi.org/10.1016/j.clindermatol.2021.01.002Pillsbury D.M., Shelley W.B. Dermatology. Annu Rev Med. 1954;5:363–88. https://dx.doi.org/10.1146/annurev.me.05.020154.002051Plewig G., Kligman A.M. Acne. Morphogenesis and Treatment. Berlin: Springer. 1975. Р. 192–3.Plewig G., Steger M. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Marks R, Plewig G, editors. Acne and Related Disorders. London: Martin Dunitz. 1989. Р. 345–57.Sabat R., Jemec G.B.E., Matusia., et al. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. https://dx.doi.org/10.1038/s41572-020-0149-1Sung K.Y., Lee S., Jeong Y., Lee S.Y. Dissecting cellulitis of the scalp: A diagnostic challenge. Arch Plast Surg. 2020;47(6):631–2. https://dx.doi.org/10.5999/aps.2020.00633Gulliver W., Zouboulis C.C., Prens E., et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343–51. https://dx.doi.org/10.1007/s11154-016-9328-5Chu Y.L., Yu S. Hidradenitis Suppurativa: An Understanding of Genetic Factors and Treatment. Biomedicines. 2024;12(2):338. https://dx.doi.org/10.3390/biomedicines12020338Frew J.W. Intrinsic factors in the pathogenesis of hidradenitis suppurativa: Genetics, hormones, and the microbiome. J Am Acad Dermatol. 2024;91(6S):S12–6. https://dx.doi.org/10.1016/j.jaad.2024.08.052Nikolakis G., Kokolakis G., Kaleta K., et al. Pathogenese der Hidradenitis suppurativa/Acne inversa [Pathogenesis of hidradenitis suppurativa/acne inversa]. Hautarzt. 2021;72(8):658–65. German. https://dx.doi.org/10.1007/s00105-021-04853-xWang Z., Yan Y., Wang B. Secretase Genetics of Hidradenitis Suppurativa: A Systematic Literature Review. Dermatology. 2021;237(5):698–704. https://dx.doi.org/10.1159/000512455Verma S.S., Sharma K., Chhabra S. Pathogenesis of Hidradenitis Suppurativa: An Immunological Perspective. Indian J Dermatol. 2023;68(3):296–300. https://dx.doi.org/10.4103/ijd.ijd_594_22Jastrz B., Szepietowski J.C., Matusiak Ł. Hidradenitis suppurativa and follicular occlusion syndrome: Where is the pathogenetic link? Clin Dermatol. 2023;41(5):576–83. https://dx.doi.org/10.1016/j.clindermatol.2023.08.021Frew J.W., Hawkes J.E., Krueger J.G. Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms. Ther Adv Chronic Dis. 2019;10:2040622319830646. https://dx.doi.org/10.1177/2040622319830646Ceruti J.M., Leirs G.J., Balana M.E. Androgens and androgen receptor action in skin and hair follicles. Mol Cell Endocrinol. 2018;465:122–33. https://dx.doi.org/10.1016/j.mce.2017.09.009Nikolakis G., Kyrgidis A., Zouboulis C.C. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol. 2019;20(4):503–13. https://dx.doi.org/10.1007/s40257-019-00442-wYook H.J., Kim E., Kim Y.H., et al. A link between smoking behaviors and the risk of hidradenitis suppurativa in diabetic patients. PLoS One. 2025;20(6):e0325357. https://dx.doi.org/10.1371/journal.pone.0325357Ng-Wong Y.K., Alexander B., Bartl M., et al. Deeper Seated Than Skin Deep: Report of a Rare Case of Follicular Occlusion Tetrad and a Literature Review. Cureus. 2023;15(5):e39474. https://dx.doi.org/10.7759/cureus.39474Tricarico P.M., Boniotto M., Genovese G., et al. An Integrated Approach to Unravel Hidradenitis Suppurativa Etiopathogenesis. Front Immunol. 2019 Apr 25;10:892. https://dx.doi.org/10.3389/fimmu.2019.00892Liu T., Li S., Ying S., et al. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front Immunol. 2020;11:594735. https://dx.doi.org/10.3389/fimmu.2020.594735Savage K.T., Flood K.S., Porter M.L., Kimball A.B. TNF-α inhibitors in the treatment of hidradenitis suppurativa. Ther Adv Chronic Dis. 2019;10:2040622319851640. https://dx.doi.org/10.1177/2040622319851640Ingram J.R. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990–8. https://dx.doi.org/10.1111/bjd.19435Хайрутдинов В.Р., Бурова С.А., Олисова О.Ю. и др. Гнойный гидраденит: обзор международных клинических рекомендаций по диагностике и лечению заболевания. Вестник дерматологии и венерологии. 2024;100(3):7–16. [Khairutdinov V.R., Burova S.A., Olisova O.Yu., et al. Suppurative hidradenitis: a review of international clinical guidelines for the diagnosis and treatment of the disease. Bulletin of Dermatology and Venereology. 2024;100(3):7–16. (In Russ.)]. https://doi.org/10.25208/vdv16739Клинические рекомендации. Гидраденит гнойный. Год утверждения 2023. [Clinical guidelines. Suppurative hidradenitis. Year of approval 2023. (In Russ.)].Mahmood F., Hussain A., Akingboye A. Pilonidal sinus disease: Review of current practice and prospects for endoscopic treatment. Ann Med Surg (Lond). 2020;57:212–7. https://dx.doi.org/10.1016/j.amsu.2020.07.050Magalhães R.F., Rivitti-Machado M.C., Duarte G.V., et al. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol. 2019;94(2 Suppl. 1):7–19. https://dx.doi.org/10.1590/abd1806-4841.20198607Alikhan A., Sayed C., Alavi A., et al. North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91–101. https://dx.doi.org/10.1016/j.jaad.2019.02.068Baran A., Kwiatkowska A., Potocki L. Antibiotics and Bacterial Resistance-A Short Story of an Endless Arms Race. Int J Mol Sci. 2023;24(6):5777. https://dx.doi.org/10.3390/ijms24065777Goldburg S.R., Strober B.E., Payette M.J. Hidradenitis suppurativa: Current and emerging treatments. J Am Acad Dermatol. 2020;82(5):1061–82. https://dx.doi.org/10.1016/j.jaad.2019.08.089Alshehri A.A., Althobaiti B.A., Khawagi W.Y., Murphy K.D. Awareness of isotretinoin use and safety in Saudi Arabia: A nationwide cross-sectional study. Saudi Pharm J. 2023;31(11):101796. https://dx.doi.org/10.1016/j.jsps.2023.101796Zouboulis C.C., Bechara F.G., Dickinson-Blok J.L., et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31. https://dx.doi.org/10.1111/jdv.15233Lucky A.W., Koltun W., Thiboutot D., et al. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment. Cutis. 2008;82(2):143–50.Riis P.T., Ring H.C., Themstrup L., Jemec G.B. The Role of Androgens and Estrogens in Hidradenitis Suppurativa - A Systematic Review. Acta Dermatovenerol Croat. 2016;24(4):239–49.Hambly R., Kearney N., Hughes R., et al. Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators. Int J Mol Sci. 2023;24(8):6969. https://dx.doi.org/10.3390/ijms24086969Petrasca A., Hambly R., Kearney N., et al. Metformin has anti-inflammatory effects and induces immunometabolic reprogramming via multiple mechanisms in hidradenitis suppurativa, Br J Dermatol. 2023;189(6):730–40. https://doi.org/10.1093/bjd/ljad305Hendricks A.J., Hsiao J.L., Lowes M.A., Shi V.Y. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96. https://dx.doi.org/10.1159/000503605Alikhan A., Sayed C., Alavi A., et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: Part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76–90. https://dx.doi.org/10.1016/j.jaad.2019.02.067Chawla S., Toale C., Мorris М., et al. Surgical management of hidradenitis suppurativa: a narrative review. J Clin Aesthet Dermatol. 2022;15(1):35–41.Yeroushalmi S., Ildardashty A., Elhage K.G., et al. Hidradenitis suppurativa and sleep: a systematic review. Arch Dermatol Res. 2023;315(5):1409–15. https://dx.doi.org/10.1007/s00403-022-02460-xDi Guida A., Forgione P., Fornaro L., et al. Step by step surgery for hidradenitis suppurativa. Dermatol Ther. 2022;35(12):e15938. https://dx.doi.org/10.1111/dth.15938Guermazi D., Shah A., Yumeen S., Saliba E. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review. Arch Dermatol Res. 2024;316(6):259. https://dx.doi.org/10.1007/s00403-024-03121-xZouboulis C.C., Okun M.M., Prens E.P., et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60–9.e2. https://dx.doi.org/10.1016/j.jaad.2018.05.040Zouboulis C.C., Bechara F.G., Dickinson-Blok J.L., et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19–31. https://dx.doi.org/10.1111/jdv.15233Schettini N., Marzola E., Pacetti L., et al. Case of Dissecting Cellulitis of the Scalp, Hidradenitis Suppurativa, and Conglobate Acne Successfully Treated with Secukinumab. Skin Appendage Disord. 2024;10(3):232–5. https://dx.doi.org/10.1159/000537914Snyder C.L., Gibson R.S., Porter M.L., Kimball A.B. Secukinumab in the treatment of hidradenitis suppurativa. Immunotherapy. 2023;15(17):1449–57. https://dx.doi.org/10.2217/imt-2023-0103Stergianou D., Kanni T., Damoulari C., et al. arellos-Bourboulis E.J. An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa. Expert Opin Biol Ther. 2024;24(4):225–32. https://dx.doi.org/10.1080/14712598.2024.2343112Lipa K., Zajac N., Witkowski G., et al. Hidradenitis suppurativa – biologic therapy and other available treatment options. Postepy Dermatol Alergol. 2023;40(4):518–28. https://dx.doi.org/10.5114/ada.2021.112075Hendricks A.J., Hsiao J.L., Lowes M.A., Shi V.Y. A Comparison of International Management Guidelines for Hidradenitis Suppurativa. Dermatology. 2021;237(1):81–96. https://dx.doi.org/10.1159/000503605Hurley H.J. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: Surgical approach. In: Dermatologic Surgery: Principles and Practice, Roenigk R.K., Roenigk H.H. (Eds), Marcel Dekker. 1989. 729 p.Prens L.M., Rondags A., Volkering R.J., et al. The refined Hurley classification: the inter-rater and intrarater reliability and face validity. Br J Dermatol. 2019;181(6):1335–7. https://dx.doi.org/10.1111/bjd.18235